The Multiple Myeloma Channel is supported with funding from AbbVie (Platinum), Sanofi (Gold), Legend Biotech (Bronze), and through an educational grant from Alexion Pharma GmbH.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
SOHO Italy 2020 | Balancing efficacy and tolerability in multiple myeloma
Patrizia Tosi, MD, Infermi Hospital, Rimini, Italy, discusses the importance of balancing efficacy and toxicity in the era of novel agents in the treatment of multiple myeloma. Dr Tosi also discusses side effects associated with monoclonal antibodies and cellular therapies such as hematological toxicities as well as highlighting belantamab mafodotin, a efficacious antibody-drug conjugate in multiple myeloma with corneal side effects. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).
